Narinder Nangia

465 total citations
16 papers, 353 citations indexed

About

Narinder Nangia is a scholar working on Pharmacology, Public Health, Environmental and Occupational Health and Epidemiology. According to data from OpenAlex, Narinder Nangia has authored 16 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 7 papers in Public Health, Environmental and Occupational Health and 5 papers in Epidemiology. Recurrent topics in Narinder Nangia's work include Treatment of Major Depression (7 papers), Opioid Use Disorder Treatment (6 papers) and Complement system in diseases (4 papers). Narinder Nangia is often cited by papers focused on Treatment of Major Depression (7 papers), Opioid Use Disorder Treatment (6 papers) and Complement system in diseases (4 papers). Narinder Nangia collaborates with scholars based in United States, Italy and Canada. Narinder Nangia's co-authors include M. Brown, David Borenstein, Miao Yu, Arielle D. Stanford, Sanjeev Pathak, Elliot Ehrich, Sarah Akerman, Bernard L. Silverman, Maria A. Sullivan and Michael E. Thase and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Statistical Association and Blood.

In The Last Decade

Narinder Nangia

16 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Narinder Nangia United States	10	130	79	69	63	48	16	353
Xiaodan Liu China	15	44 0.3×	25 0.3×	42 0.6×	29 0.5×	31 0.6×	36	439
Ercan Yılmaz Türkiye	14	81 0.6×	111 1.4×	92 1.3×	12 0.2×	58 1.2×	45	615
Hassan Kahal United Kingdom	12	51 0.4×	77 1.0×	22 0.3×	27 0.4×	73 1.5×	28	545
Péter Takács Hungary	12	40 0.3×	28 0.4×	148 2.1×	32 0.5×	35 0.7×	23	480
Kazumi Fujita Japan	7	39 0.3×	15 0.2×	36 0.5×	18 0.3×	27 0.6×	12	368
Michela Mariani Italy	8	52 0.4×	61 0.8×	77 1.1×	11 0.2×	43 0.9×	26	414
Yu Qian China	11	19 0.1×	24 0.3×	38 0.6×	24 0.4×	34 0.7×	33	297
Elif Kılıç Türkiye	13	17 0.1×	35 0.4×	39 0.6×	20 0.3×	69 1.4×	33	407
Zhenglun Pan China	7	20 0.2×	22 0.3×	34 0.5×	15 0.2×	15 0.3×	10	308

Countries citing papers authored by Narinder Nangia

Since Specialization

Citations

This map shows the geographic impact of Narinder Nangia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narinder Nangia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narinder Nangia more than expected).

Fields of papers citing papers by Narinder Nangia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narinder Nangia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narinder Nangia. The network helps show where Narinder Nangia may publish in the future.

Co-authorship network of co-authors of Narinder Nangia

This figure shows the co-authorship network connecting the top 25 collaborators of Narinder Nangia. A scholar is included among the top collaborators of Narinder Nangia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narinder Nangia. Narinder Nangia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Schoettler, Michelle Long, Narinder Nangia, Miguel‐Angel Perales, et al.. (2025). Narsoplimab Treatment for Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy (TA-TMA) – Real World Outcomes from an Expanded Access Program. Transplantation and Cellular Therapy. 31(2). S25–S25. 1 indexed citations

Schoettler, Michelle Long, Narinder Nangia, Miguel‐Angel Perales, et al.. (2025). Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy ( TA ‐ TMA ). American Journal of Hematology. 100(11). 2040–2051. 2 indexed citations

Lysak, Zoreslava, Narinder Nangia, Charlotte A. Osborne, et al.. (2023). OMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Naïve PNH Patients. Blood. 142(Supplement 1). 573–573. 4 indexed citations

Khaled, Samer K., Kathleen Claes, Yeow Tee Goh, et al.. (2022). Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy. Journal of Clinical Oncology. 40(22). 2447–2457. 66 indexed citations

Comer, Sandra D., Paolo Mannelli, Danesh Alam, et al.. (2020). Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. American Journal on Addictions. 29(4). 313–322. 9 indexed citations

Kosten, Thomas R., Efrat Aharonovich, Narinder Nangia, et al.. (2020). Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. Addictive Behaviors. 111. 106538–106538. 4 indexed citations

Sun, Lei, Narinder Nangia, David McDonnell, et al.. (2020). Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 100. 109881–109881. 14 indexed citations

Nunes, Edward V., Adam Bisaga, Evgeny Krupitsky, et al.. (2019). Opioid use and dropout from extended‐release naltrexone in a controlled trial: implications for mechanism. Addiction. 115(2). 239–246. 15 indexed citations

Naismith, Robert T., Jerry S. Wolinsky, Annette Wundes, et al.. (2019). Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis Journal. 26(13). 1729–1739. 47 indexed citations

10.

Pathak, Sanjeev, Bradley Vince, Debra Kelsh, et al.. (2018). Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial. The Journal of Clinical Pharmacology. 59(2). 206–217. 8 indexed citations

11.

Pathak, Sanjeev, Bradley Vince, Debra Kelsh, et al.. (2018). Abuse Potential of Samidorphan: A Phase I, Oxycodone‐, Pentazocine‐, Naltrexone‐, and Placebo‐Controlled Study. The Journal of Clinical Pharmacology. 59(2). 218–228. 11 indexed citations

12.

Bisaga, Adam, Paolo Mannelli, Miao Yu, et al.. (2018). Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug and Alcohol Dependence. 187. 171–178. 34 indexed citations

13.

Fava, Maurizio, Michael E. Thase, Madhukar H. Trivedi, et al.. (2018). Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. Molecular Psychiatry. 25(7). 1580–1591. 59 indexed citations

14.

Naismith, Robert T., Richard Leigh-Pemberton, Narinder Nangia, et al.. (2018). EVOLVE-MS-1: A Phase 3, Open-Label, Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis (P6.360). Neurology. 90(15_supplement). 1 indexed citations

15.

Borenstein, David, et al.. (2004). Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. Clinical Therapeutics. 26(8). 1249–1260. 63 indexed citations

16.

Ghosh, Malay, Narinder Nangia, & Dal Ho Kim. (1996). Estimation of Median Income of Four-Person Families: A Bayesian Time Series Approach. Journal of the American Statistical Association. 91(436). 1423–1423. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact